The research aims to characterize interactions between pertactin-specific antibodies and their antigens to advance vaccine and therapeutic designs.
Screening for pertactin-specific antibodies
Utilizing native mass spectrometry for structural analysis
Evaluating competitive recognition of epitopes
Identified specific antibody recognition patterns
Characterized binding interactions of mAbs
Demonstrated potential for optimizing vaccine efficacy
Abstract
Structural characterization of antigen–antibody interactions is critical for understanding protective vaccine responses and development of therapeutic monoclonal antibodies (mAb).